The U.S. Food and Drug Administration signed a new contract on July 25 to acquire “fresh” human fetal tissue to transplant into “humanized mice” so that these mice will have a functioning “human immune system,” according to information published by the FDA and the General Services Administration.
“The objective is to acquire Tissue for Humanized Mice,” said a June 13 FDA “presolicitation notice” for the contract.
The contractor, the notice said, would “provide the human fetal tissue needed to continue the ongoing research being led by FDA.
“Fresh human tissues are required,” said the notice, “for implantation into severely immune-compromised mice to create chimeric animals that have a human immune system.”
According to GSA’s federal contract database, Advanced Bioscience Resources (ABR), a non-profit organization based in the San Francisco Bay Area, was awarded this $15,900 contract, which will run through July 25, 2019.
“Fetal tissue used in research is obtained from elective abortions,” says the Congressional Research Service.
In 2016, Harvard University provided the House Energy and Commerce Committee’s Select Investigative Panel on Infant Lives with a background paper explaining that mice with human immune systems “are engineered to this condition only by means of the use of human fetal material” and that this material can only come from aborted babies not from miscarriages.
Thus, by issuing a contract to acquire human fetal tissue to use in making mice with human immune systems, the FDA is using federal tax dollars to create a demand for human body parts that must be taken from babies who are aborted.
Because it would not be able to create its “humanized mice” without fresh tissue taken from aborted babies, the FDA also has an interest in the continuation of legalized abortions at a stage in fetal development when the tissue needed to create these mice can be retrieved from the aborted baby.
In fiscal 2018, the NIH—which is a separate entity from the FDA but also a part of the Department of Health and Human Services–estimates it will spend $103 million on human fetal tissue research. In fiscal 2017, it spent $98 million.
On Sept. 14, 2017, the House of Representatives passed an omnibus appropriations bill that included language pushed by Rep. Martha Roby (R.-Ala.) and other pro-life House members that would have prohibited federal funding of research that uses tissue from aborted babies. This language, however, was not included in any of the spending bills that ultimately passed the Senate and were signed into law for fiscal 2018.
We are “Soylent Green”!
Now available at amazon.com; “A Republic, if you can keep it”
Follow me on Twitter @OzarksAuthor
This page and its links contain opinion. As with all opinion, it should not be relied upon without independent verification. Think for yourself. Fair Use is relied upon for all content. For educational purposes only. No claims are made to the properties of third parties.
(c) 2018 Uriel Press